IL17A and Arthritis: In the AIA rat model of arthritis, celastrol treatment (3 g/kg/day) suppressed the expression of the proinflammatory cytokines IL-6, IL-17, and IFN-γ, reduced MMP-9 activity, and reduced serum levels of anticyclic citrullinated peptide (aCCP) antibodies [114].